Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-05-02

Clinical Trial Update: Study of the Safety and Effectiveness of Rilonacept for the Prevention of Gout Flares [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the safety and effectiveness of rilonacept for preventing gout flares completed; results were posted May 2, 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Arcalyst (rilonacept)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Gout | Phase 2 | Status: COMPLETED | Results posted: 2017-05-02